Welcome to the e-CCO Library!

DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dignass, A.(1)*;Regueiro, M.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Vermeire, S.(5);Rubin, D.T.(6);
Created: Friday, 14 July 2023, 10:43 AM
DOP43: Impact of Inflammatory Bowel Diseases on the phenotype and severity of psoriasis and spondyloarthropathies
Year: 2021
Source: ECCO'21 Virtual
Authors: Attauabi, M.(1,2,3);Damsgaard Wewer, M.(1,3);Bendtsen, F.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. T. Rubin1, M. C. Dubinsky2, M. Lukas*3, D. Quirk4, C. I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, H. Fan4, D. A. Woodworth4, G. Chan4, C. Su4

Created: Friday, 22 February 2019, 9:41 AM
DOP43: Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North
Year: 2022
Source: ECCO'22
Authors: Siegmund, B.(1);Axelrad, J.(2);Pondel, M.(3);Osterman, M.T.(3);Ahmad, H.A.(3);Memaj, A.(3);Regueiro, M.(4);Armuzzi, A.(5);Afzali, A.(6);
Created: Friday, 11 February 2022, 3:52 PM
DOP44 Cancer risk in a high-incidence inflammatory bowel disease population: a Faroese IBD cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.M.M. Midjord1, A.G. Vang2, T. Hammer3, J. Burisch1, K.R. Nielsen1, The Faroese IBD Study Group

Created: Thursday, 30 January 2020, 10:12 AM
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Rodriguez-Lago*1, J. Castro-Poceiro2, A. Fernández-Clotet2, F. Mesonero3, A. López-Sanromán3, A. López-García4, L. Márquez4, A. Clos-Parals5, F. Cañete5, M. Vicuña6, Ó. Nantes6, O. Merino7, V. Matallana Royo8, J. Gordillo9, A. Elorza1, R. Vicente10, M. J. Casanova11,12, R. Ferreiro-Iglesias13, P. Pérez-Galindo14, J. M. Benítez15,16, C. Taxonera17, M. J. García García18, E. Martín Arranz19, M. Calafat20, A. Martín-Cardona21,22, F. Muñoz Núñez23, J. O. Miquel-Cusachs24, E. Sáinz Arnau25, J. P. Gisbert11, Young IBD Group from GETECCU1

Created: Friday, 22 February 2019, 9:41 AM
DOP44: Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRN
Year: 2021
Source: ECCO'21 Virtual
Authors: Magen Rimon, R.(1);Atia, O.(2);Friss, C.(2);Ledderman, N.(3);Greenfeld, S.(4);Kariv, R.(4);Loewenberg Weisband, Y.(5);Gabay, C.(5);Shaoul, R.(1);Odes, S.(6);Matz, E.(7);Dotan, I.(8);Turner, D.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP44: Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Danese, S.(1);Colombel, J.F.(2);Ponich, T.(3);Jovanovic, I.(4);Bossuyt, P.(5);Longman, R.(6);Alekseeva, O.(7);Petersen, A.(8);Chitkara, D.(8);Marta, C.(8);Charles, L.(8);Rubin, D.T.(9);Afzali, A.(10);Loftus, E.V.(11);Wolf, D.C.(12);
Created: Friday, 11 February 2022, 3:52 PM
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: SinghD.M., A.(1)*;Midha, V.(2);Mahajan, R.(1);Kaur, K.(3);Singh, D.(4);Sood, A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Verdon1, J. Reinglas1, C. Filliter1, J. Coulombe1, L. Gonczi2, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, T. Bessissow1, P. Brassard1, P.L. Lakatos PhD1,2

Created: Thursday, 30 January 2020, 10:12 AM
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Vande Casteele*1,2, K. Papamichael3, J. Jeyarajah2, M. T. Osterman4, A. S. Cheifetz3

Created: Friday, 22 February 2019, 9:41 AM
DOP45: Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis
Year: 2022
Source: ECCO'22
Authors: Armuzzi, A.(1);Cross, R.K.(2);Lichtenstein, G.(3);Calkwood, J.(4);Pai, A.(5);Pondel, M.(5);Ahmad, H.A.(5);Charles, L.(5);Elegbe, A.(5);Petersen, A.(5);Sheffield, J.K.(5);Javed, A.(6);Hou, J.(7);Regueiro, M.(8);Wolf, D.C.(9);Long, M.(10);
Created: Friday, 11 February 2022, 3:52 PM
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Matsuoka, K.(1)*;Löwenberg, M.(2);Fumery, M.(3);Takatori, Y.(4);Fujitani, Y.(4);Oortwijn, A.(5);Faes, M.(6);Jamoul, C.(6);Hibi, T.(7);
Created: Friday, 14 July 2023, 10:43 AM
DOP45: Utilization and sustainability of biologics in CD - A nationwide study from the epi-IIRN
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Yogev, D.(1);Chagit, F.(1);Gili, F.(1); Orlanski-Meyer, E.(1);Magen Rimon, R.(2);Natan, L.(3);Shira, G.(4); Kariv, R.(4);Yisca, L.W.(5); Gabay, H.(5); Nevo, D.(6); Matz, E.(7); Gorelik, Y.(8); Chowers, Y.(8);Iris, D.(9);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP46 Impact of a genetic burden on familial aggregation of inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H.S. Lee1,2, L. Hannes1, M. Vancamelbeke3, V. Ballet4, M. Ferrante3,4, S. Vermeire3,4, I. Cleynen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn*1, M. Ferrante2, B. R. Bhandari3, E. Berliba4, T. Hibi5, G. Geert. R. D’Haens6, J. Tuttle7, K. Krueger8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9

Created: Friday, 22 February 2019, 9:41 AM
DOP46: Metabolic adaptation to ER stress licences STING signalling in intestinal epithelial cells
Year: 2022
Source: ECCO'22
Authors: Wottawa, F.(1);Becker, B.(2);Bakr, M.(1);Kugler, J.(1);Mayr, L.(3);Paludan, S.(4);Blumberg, R.(5);Kaser, A.(6);Adolph, T.(3);Schreiber, S.(7);Meiser, J.(2);Rosenstiel, P.(1);Aden, K.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bourgonje, A.(1)*;Hu, S.(1);Gacesa, R.(1);Jansen, B.H.(1);Björk, J.R.(1);Bangma, A.(1);Hidding, I.J.(1);van Dullemen, H.M.(1);Visschedijk, M.C.(1);Faber, K.N.(1);Dijkstra, G.(1);Harmsen, H.J.M.(2);Festen, E.A.M.(1);Vich Vila, A.(1);Spekhorst, L.M.(1);Weersma, R.K.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP46: Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Friss, C.(1);Mendelovici, A.(1); Shteyer, E.(1); Yogev, D.(1);Ledderman, N.(2); Greenfeld, S.(3); Kariv, R.(3); Loewenberg Weisband, Y.(4); Gabay, H.(4); Nevo, D.(5); Matz, E.(6); Dotan, I.(7);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP47 The changing pattern of inflammatory bowel disease incidence in Northern France: A continuing increase in the young women (1988–2014)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. CRETIN1, H. Sarter2, G. Savoye3, M. Fumery4, A. Leroyer2, L. Dauchet2, B. Pariente5, C. Gower-Rousseau2

Created: Thursday, 30 January 2020, 10:12 AM